Blood Test Combining Cytokines and Vitamin D Could Flag Complex Febrile Seizures in Children

Febrile seizures are among the most common neurological events of early childhood, affecting a substantial proportion of children between six months and five years of age during fever-inducing illnesses. For decades, clinicians have separated these events into two broad categories: simple febrile seizures, which are generalized, last less than fifteen minutes, and do not recur within twenty-four hours, and complex febrile seizures, which are prolonged, focal, or recurrent within the same febrile episode. The distinction matters enormously at the bedside, because complex events carry a higher likelihood of subsequent epilepsy, greater need for neuroimaging and extended observation, and more intensive counseling for anxious families. Yet the classification depends almost entirely on seizure history reported by frightened parents or observed incompletely by emergency staff, and that history is notoriously unreliable. A new study from pediatric researchers at Shijiazhuang People’s Hospital in China, published in BMC Pediatrics, now proposes a blood-based solution: a statistical tool built from three measurable serum markers that could help physicians classify a seizure objectively within minutes of admission.

The research team, led by Meng Xie and corresponding author Li Zhao, enrolled 219 children who presented with febrile seizures between January 2023 and December 2024. Of these, 118 had simple febrile seizures and 101 had complex febrile seizures. The investigators drew blood within thirty minutes of admission and measured serum concentrations of the pro-inflammatory cytokines interleukin-1 beta and interleukin-6, along with 25-hydroxyvitamin D, the standard circulating measure of vitamin D status. Additional inflammatory biomarkers were assayed as candidate predictors. The design was retrospective and single-center, meaning the children were identified from existing clinical records rather than followed prospectively, and all measurements came from a single hospital laboratory, an important caveat when generalizing the findings to other settings with different assay platforms and patient populations.

The biological rationale for choosing these three markers is grounded in what is known about the neuroimmunology of febrile seizures. Interleukin-1 beta is a central mediator of fever and neuronal excitability; it promotes the release of prostaglandin E2 in the hypothalamus and can enhance glutamatergic signaling in the hippocampus, lowering the seizure threshold during fever. Interleukin-6, by contrast, has a more complicated dual role, participating in both pro- and anti-inflammatory signaling in the central nervous system. Vitamin D adds a third dimension, because the active hormonal form of the vitamin regulates immune responses and has documented anticonvulsant and neuroprotective properties, while deficiency states have been repeatedly linked to increased seizure susceptibility in pediatric populations. The study’s central question was whether the combined pattern of these three circulating factors could discriminate between the two seizure types better than any single marker or clinical impression alone.

Using multivariable logistic regression, the researchers identified all three markers as independent predictors of complex febrile seizures, each with a distinct directional signature. Higher interleukin-1 beta levels were associated with increased odds of a complex seizure, with an adjusted odds ratio of 1.085 per unit increase, a 95 percent confidence interval of 1.042 to 1.130, and a p value below 0.001. Interleukin-6 and 25-hydroxyvitamin D moved in the opposite direction: both were independently associated with lower odds of complex febrile seizures, with adjusted odds ratios of 0.919 and 0.889 respectively, and both confidence intervals excluding the null value. The inverse association for interleukin-6 is intriguing and may reflect its immunoregulatory, anti-inflammatory arm becoming dominant in children whose febrile response is more contained, though the authors present the association as predictive rather than mechanistic.

From these regression coefficients the team constructed a nomogram, a graphical scoring instrument that converts a patient’s individual biomarker values into points, sums them, and translates the total into an estimated probability of complex febrile seizure. Nomograms have long been popular in oncology risk prediction and are increasingly applied to pediatric diagnostics because they compress a multivariable model into a single bedside-usable chart that requires no calculator or software. In this case, a physician measuring interleukin-1 beta, interleukin-6, and 25-hydroxyvitamin D on admission could read off a percentage that quantifies how likely the seizure is to be complex, supplementing the clinical history rather than replacing it.

The model’s performance statistics were strong for a three-variable biomarker panel. The area under the receiver operating characteristic curve, a standard measure of discrimination that expresses the probability that a randomly chosen complex case is ranked above a randomly chosen simple case, reached 0.860 with a 95 percent confidence interval of 0.813 to 0.907. This combined score significantly outperformed each individual biomarker on its own, with all pairwise comparisons reaching statistical significance. At the optimal cutoff of 61.3 percent predicted probability, the model achieved a sensitivity of 84.2 percent, correctly identifying most complex seizures, and a specificity of 77.1 percent, correctly clearing most simple ones. In practical terms, roughly five out of six complex febrile seizures would be flagged by the tool, while about three of four simple seizures would be correctly classified as low risk.

Discrimination alone is not sufficient for a clinical prediction tool, and the authors addressed this with two additional analyses. Calibration, the agreement between predicted probabilities and observed outcomes, was assessed with the Hosmer-Lemeshow test, which yielded a chi-square statistic of 13.848 with eight degrees of freedom and a p value of 0.086, indicating no statistically significant miscalibration. Decision curve analysis, a method that quantifies the net clinical benefit of acting on a model’s predictions across a range of decision thresholds, confirmed a positive net benefit across clinically relevant probabilities. To guard against overfitting in a modest sample, the team employed 1000 bootstrap resampling iterations for internal validation, a standard technique that simulates repeated sampling from the same population to estimate how the model would perform on new patients from the same source.

One of the more clinically important findings concerns age. Febrile seizure guidelines and prognosis differ meaningfully between younger and older children, and any risk tool that behaves inconsistently across age strata would be difficult to deploy. The researchers therefore performed subgroup analyses dividing the cohort into children aged three years or younger and children older than three, and supplemented this with continuous interaction testing for effect modification. The model’s discrimination was nearly identical across the two strata, with AUCs of 0.860 and 0.865 respectively, and all interaction p values exceeded 0.05, indicating that the biomarker relationships did not differ significantly by age. The authors also report that performance remained consistent across subtypes of complex febrile seizures, strengthening the case for the tool’s general applicability within the studied population.

The implications, if the findings are replicated, could be substantial for emergency pediatric care. A rapid, objective classification at the front door could guide decisions about lumbar puncture, neuroimaging, admission versus discharge, duration of observation, and the intensity of parental counseling, potentially reducing both unnecessary interventions for low-risk children and premature discharge of high-risk ones. The authors are careful to frame the nomogram as an adjunctive risk-stratification instrument, and they note a practical constraint: its use depends on the availability of rapid multiplex cytokine testing, which is not yet routine in many emergency departments. The retrospective, single-center design, the modest sample of 219 children, and the need for external validation in independent cohorts with different ethnic, geographic, and laboratory contexts all temper enthusiasm appropriately. Still, the study adds to a growing literature suggesting that the immune fingerprint of a febrile illness, read through a handful of serum markers, carries information that clinical history alone cannot provide.

The work also highlights a broader shift in pediatric neurology toward quantitative, biomarker-informed risk stratification. Where previous generations of clinicians relied on seizure semiology recalled under stress, the combination of interleukin-1 beta, interleukin-6, and vitamin D offers a measurable, reproducible snapshot of the host response at the moment of presentation. The research was funded by the Scientific Research Fund of the Hebei Health Commission, received ethical approval from Shijiazhuang People’s Hospital, and was published open access, making the full model details available to other research groups seeking to validate or refine the approach. Whether this particular three-marker panel becomes standard practice will depend on prospective multicenter trials, but the study demonstrates that a simple, transparent statistical tool built from routine blood tests can meaningfully sharpen one of the most common and consequential diagnostic judgments in pediatric emergency medicine.

Subject of Research: A biomarker-based nomogram for differentiating complex from simple febrile seizures in children

Article Title: A nomogram integrating IL‑1β, IL‑6, and vitamin D for differentiating complex from simple febrile seizures

Article References: Xie, M., Shi, J., Zhang, Y., Yang, Y., & Zhao, L. (2026). A nomogram integrating IL‑1β, IL‑6, and vitamin D for differentiating complex from simple febrile seizures. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07838-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07838-8

Keywords: febrile seizures, IL-1β, IL-6, vitamin D, nomogram, pediatrics, biomarkers, risk prediction, inflammation, 25-hydroxyvitamin D, logistic regression, emergency medicine